Evidence map›Paper›PMID 34006898›Full record

Trial reportScientific reports2021

Comparison of metabolic changes after neoadjuvant endocrine and chemotherapy in ER-positive, HER2-negative breast cancer.

Ho Hyun Ryu, Sei Hyun Ahn, Seon Ok Kim, Jeong Eun Kim, Ji Sun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim, Beom Seok Ko, Jong Won Lee and 5 more

Open access · goldAbstract readClinical Trial, Phase IIIComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Ho Hyun RyuDepartment of Breast Surgery, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, Korea.
Sei Hyun AhnDepartment of Breast Surgery, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, Korea.
Seon Ok KimDepartment of Clinical Epidemiology and Biostatistics, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Jeong Eun KimDepartment of Oncology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Ji Sun KimDepartment of Breast Surgery, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, Korea.
Jin-Hee AhnDepartment of Oncology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Kyung Hae JungDepartment of Oncology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Sung-Bae KimDepartment of Oncology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Beom Seok KoDepartment of Breast Surgery, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, Korea.
Jong Won LeeDepartment of Breast Surgery, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, Korea.
Byung Ho SonDepartment of Breast Surgery, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, Korea.
Hee Jung ShinDepartment of Radiology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Hak Hee KimDepartment of Radiology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Gyung Yub GongDepartment of Pathology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Korea.
Hee Jeong KimDepartment of Breast Surgery, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic ro 43 gil, song pa gu, Seoul, 138-736, Korea. haapybirth@amc.seoul.kr.
Asan Medical Center · KRUniversity of Ulsan · KRUlsan College · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Survival of breast cancer patients has improved, and treatment-related changes regarding metabolic profile deterioration after neoadjuvant systemic treatment (NST) become important issues in cancer survivors. We sought to compare metabolic profile changes and the neutrophil-to-lymphocyte ratio (NLR) between patients undergoing neoadjuvant chemotherapy (NCT) and neoadjuvant endocrine therapy (NET) 3 years after the treatment. In a prospective, randomized, phase III trial which compared 24 weeks of NCT with adriamycin and cyclophosphamide followed by docetaxel and NET with goserelin and tamoxifen (NEST), 123 patients in the Asan Medical Center were retrospectively reviewed to evaluate metabolic changes, such as body mass index (BMI), blood pressure (BP), total cholesterol (TC), fasting glucose, and the NLR. The mean age of patients was 42 years. The changes in BMI, serum glucose, and TC during NST and after 3 years were significantly different between NCT and NET. The proportion of overweight + obese group and the mean BMI were significantly increased during NCT (26.6% to 37.5%, 22.84 kg/m

Indexed as

Neoadjuvant TherapyAdultAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCyclophosphamideDoxorubicinErb-b2 Receptor Tyrosine KinasesFemaleGoserelinHumansMiddle AgedProspective StudiesReceptors, EstrogenTamoxifenCyclophosphamideDoxorubicinErb-b2 Receptor Tyrosine KinasesGoserelinReceptors, EstrogenTamoxifen

Identifiers

PMID34006898
PMCPMC8131718
OpenAlexW3163779191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.